Summit Therapeutics PLC (SMMT) — Capital Reinvestment Ratio
Latest as of December 2022:
0.23x
Summit Therapeutics PLC (SMMT) has a Capital Reinvestment Ratio of 0.23x as of December 2022, meaning it reinvests 0% of its operating cash flow ($4.23 Million) in capital expenditures ($994.38K). See Summit Therapeutics PLC free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.23x
Capex / Operating Cash Flow
Operating Cash Flow
$4.23 Million
USD
Capital Expenditures
$994.38K
USD
Data as of
Dec 2022
Most recent filing
Summit Therapeutics PLC Capital Reinvestment Ratio (2004–2016)
This chart tracks Summit Therapeutics PLC's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Summit Therapeutics PLC (2004–2016)
Year-by-year Capital Reinvestment Ratio for Summit Therapeutics PLC from 2004 to 2016. For live market cap and broader valuation context, see how much is Summit Therapeutics PLC worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2016 | 0.01x | $15.18 Million | $110.00K | ▼ -98.4% |
| 2004 | 0.44x | $29.74K | $13.18K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow